Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
RESEARCH TOOLSreports
Holding HOWL?
Track your performance easily
HOWL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.57 - $8.19
Previous Close$2.22
Volume101.95K
Average Volume (3M)301.87K
Market Cap
$97.02M
Enterprise Value-$1.61M
Total Cash (Recent Filing)$135.30M
Total Debt (Recent Filing)$36.68M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 07, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding43,702,147
10 Day Avg. Volume100,511
30 Day Avg. Volume301,866
Standard Deviation0.27
R-Squared0.00701
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.93
Price to Sales (P/S)10.50
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.27
Enterprise Value/Gross Profit-1.03
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$12.50Price Target Upside425.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Werewolf Therapeutics News
PremiumCompany Announcements
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes
PremiumCompany Announcements
Werewolf Therapeutics’ Promising WTX-124 Clinical Trial OutcomesBulls Say, Bears Say
Bulls Say
Clinical EfficacyWTX-124 demonstrated anti-tumor activity in a cutaneous squamous cell carcinoma patient dosed at 12 mg, with a previously unconfirmed PR achieving a CR.
Investment OpportunityUpdated data showcasing the safety of WTX-124, first-in-human clinical data for WTX-330 expected, a partnership with Jazz Pharmaceuticals, and a cash position at $125.4MM represent a unique investment opportunity.
Safety DataEncouraging safety updates further validate its platform.
Bears Say
Adverse EventsTwo patients experienced reversible dose-limiting toxicities, including grade 3 mucositis and a grade 3 AST increase at 3,200 ng/kg.
Clinical ProgressionA melanoma patient dosed at 12 mg with a previous unconfirmed partial response progressed at week 16, showing new lesions near the sternum and portal vein.
Efficacy DataEarly monotherapy efficacy data for both programs did not live up to investors' expectations, and WTX-330 data suggests a narrower therapeutic window for masked native IL-12.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $1.57 and its highest was $8.19 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Currently, no data Available
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.054.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -$0.41.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 43,702,150 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 8.187%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Among the largest hedge funds holding Werewolf Therapeutics’s share is RA Capital Management. It holds Werewolf Therapeutics’s shares valued at 15M.
---
Werewolf Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (425.21% Upside)
$12.50 (425.21% Upside)
Blogger Sentiment
Bullish
HOWL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 88.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.01%
12-Months-Change
Fundamentals
Return on Equity
-48.27%
Trailing 12-Months
Asset Growth
-17.02%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
---
HOWL Stock 12 Month Forecast
Average Price Target
$12.50
▲(425.21% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Karyopharm Therapeutics
―
TFF Pharmaceuticals
―
GlycoMimetics
―
Best Analysts Covering HOWL
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
-1.33%
reiterated a buy rating last month
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -1.33% per trade.
---